National Bank of Canada
SMMT icon

National Bank of Canada’s Summit Therapeutics SMMT Stock Holding History

National Bank of Canada’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$42.2K Buy
2,223
+528
+31% +$8.54K ﹤0.01% 2024
2025
Q4 		$29.6K Buy
1,695
+931
+122% +$17.5K ﹤0.01% 2068
2025
Q3 		$15.8K Buy
764
+47
+7% +$1.14K ﹤0.01% 2213
2025
Q2 		$15.3K Buy
717
+209
+41% +$4.77K ﹤0.01% 2242
2025
Q1 		$9.8K Sell
508
-1,156
-69% -$23.2K ﹤0.01% 2255
2024
Q4 		$29.7K Buy
+1,664
New +$32.3K ﹤0.01% 2083
2024
Q3 		– Sell
-1,600
Closed -$13K – 3011
2024
Q2 		$13K Hold
1,600
– – ﹤0.01% 2072
2024
Q1 		$7.44K Hold
1,600
– – ﹤0.01% 2234
2023
Q4 		$4.22K Hold
1,600
– – ﹤0.01% 2336
2023
Q3 		$2.81K Hold
1,600
– – ﹤0.01% 2466
2023
Q2 		$4.01K Hold
1,600
– – ﹤0.01% 2380
2023
Q1 		$2.77K Sell
1,600
-1,641
-51% -$4.47K ﹤0.01% 2389
2022
Q4 		$13.7K Hold
3,241
– – ﹤0.01% 2093
2022
Q3 		$4K Hold
3,241
– – ﹤0.01% 2400
2022
Q2 		$3K Hold
3,241
– – ﹤0.01% 2557
2022
Q1 		$8K Hold
3,241
– – ﹤0.01% 2447
2021
Q4 		$9K Buy
+3,241
New +$15.6K ﹤0.01% 2402

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

National Bank of Canada's SMMT Position: Q1 2026 in Review

National Bank of Canada increased its Summit Therapeutics (SMMT) stake by 31% in Q1 2026, buying an estimated $8.54K and bringing the position to 2,223 shares worth $42.2K. The position accounts for ﹤0.01% of the portfolio, ranked #2024.

National Bank of Canada first reported a position in SMMT in Q4 2021 and has held it in 17 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

  • National Bank of Canada held 2,223 shares of Summit Therapeutics worth $42.2K as of Q1 2026.
  • National Bank of Canada bought 528 Summit Therapeutics shares in Q1 2026, an estimated $8.54K.
  • Summit Therapeutics made up ﹤0.01% of National Bank of Canada's portfolio in Q1 2026, its #2024 holding.
  • National Bank of Canada first reported a position in Summit Therapeutics in Q4 2021 and has held it in 17 quarters since.
  • 222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on National Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.